

Informazione Regolamentata n. 20106-46-2024	Data/Ora Inizio Diffusione 4 Novembre 2024 08:34:54	Euronext Star Milan
---	--	---------------------

Societa' : PHARMANUTRA

Identificativo Informazione  
Regolamentata : 197502

Utenza - Referente : PHARMANUTRAN04 - Roberto Lacorte

Tipologia : REGEM

Data/Ora Ricezione : 4 Novembre 2024 08:34:54

Data/Ora Inizio Diffusione : 4 Novembre 2024 08:34:54

Oggetto : Pharmanutra: Launch of new products

*Testo del comunicato*

Vedi allegato

## PHARMANUTRA S.p.A. APPLIES ITS PROPRIETARY SUCROSOMIAL® TECHNOLOGY TO VITAMINS AND LAUNCHES NEW SIDEVIT® LINE

**IN ADDITION TO THE FIRST SUCROSOMIAL® VITAMINS SIDEVIT® D3 AND SIDEVIT® B12, THE  
COMPANY ALSO UNVEILED SUPPLEMENTS SIDERAL® MAMMA AND LACTOPAM®**

Pisa, November 4, 2024 – [PharmaNutra S.p.A.](#) (MTA; Ticker PHN), a company specializing in nutritional supplements based on minerals and medical devices for muscles and joints, announces the launch of its expanded product range with the introduction of the new Sidevit® line (Sidevit® D3 and Sidevit® B12), SiderAL® Mamma, and Lactopam®.

As anticipated at the beginning of October in Milan, during the latest CPHI, Sidevit® is the first line of Sucrosomial® Vitamins, the result of significant investments made in recent years in R&D activities that have allowed PharmaNutra to apply its patented Sucrosomial® Technology - previously used successfully for minerals (iron, magnesium, zinc, etc.) - also to certain vitamins. The first results of this research are Sidevit® D3, a food supplement based on Sucrosomial® Vitamin D3 in tablets, and Sidevit® B12, a food supplement based on Sucrosomial® Vitamin B12 and Folic Acid in orodispersible sachets, nutritional supplements designed to effectively address deficiencies of these two essential nutrients, and characterized by high bioavailability, maximum concentration, and patented technology.

Specifically, Sidevit® D3 contains 2000IU of vitamin D3, the dosage recommended by scientific companies, which, due to its evidently higher absorption than conventional vitamin D3, allows it to be absorbed more quickly and in greater quantities, reaching a higher concentration in the blood and a longer half-life compared to other formulations available on the market. Sidevit® B12, an essential supply for activating our energy metabolism and proper red blood cell production, showed significantly higher serum concentrations after oral intake than conventional vitamin B12, essential for the body in case of physical and mental fatigue or muscle weakness, when its intake is reduced due to strict diets and in case of anemia or problems related to nutrient absorption.

In addition to the first products of the new Sidevit® line, PharmaNutra has also launched SiderAL® Mamma and Lactopam® on the Italian market. The former represents an expansion of the SiderAL® line and is a food supplement in capsules based on Sucrosomial® Iron, plant-based DHA, vitamins, minerals, and folic acid, designed to support the nutrient needs during pregnancy and breastfeeding. An advanced

and complete formulation, highly tolerable, perfectly able to meet the needs of both mother and child.

Lactopam®, on the other hand, is the new food supplement in tablets based on Lactium® (hydrolyzed milk proteins) and Sucrosomial® Magnesium, a highly innovative formulation designed to promote sleep and nighttime rest.

**Andrea Lacorte, President of PharmaNutra S.p.A., states:** *“We are truly proud to launch the new line of Sucrosomial® Vitamins on the market, as it is yet another tangible result of the great attention that the PharmaNutra Group devotes to research and development. We knew very well that the idea of applying our Sucrosomial® Technology, whose effectiveness is now recognized worldwide, also to vitamins, had enormous potential, and this pushed us to work with extraordinary dedication to develop this line of products which, thanks to its extraordinary characteristics, will surely have the success it deserves”.*

#### PharmaNutra S.p.A.

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. PharmaNutra is a leader in the production of iron-based nutritional supplements with the SiderAL® brand, where it can claim important Sucrosomial® Technology patents, and is considered one of the top players in the sector of medical devices dedicated to the restoration of joint capacity thanks to the Cetilar® brand, now on the market also with Cetilar® Nutrition, a line of supplements designed for those who practice sport constantly. Over the years the Group - present abroad in over 80 countries - has developed precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

[PharmaNutra.it](http://PharmaNutra.it)

For further information:

#### PharmaNutra S.p.A.

Via Delle Lenze, 216/b - 56122 Pisa  
Tel. +39 050 7846500  
[investorrelation@pharmanutra.it](mailto:investorrelation@pharmanutra.it)

Internal Press Office  
[press@calabughi.com](mailto:press@calabughi.com)

#### Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan  
Tel. +39 02 83635708

Matteo Russo  
[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)  
Cristina Tronconi  
[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)

Fine Comunicato n.20106-46-2024

Numero di Pagine: 4